Market Intel: Expanding Elderly Population Gives Leg Up To Osteoporosis Dx Growth
The global market for osteoporosis diagnostic products is expected to expand from $253m in 2015 to $304m by 2020, fueled by a rising aging population and the need to test for osteoporosis and associated fracture risk. This article offers an in-depth look at the growth markets for both bone densitometer testing and biochemical marker tests, as well as the evolving competitive landscape, and the drivers and barriers to market entry.
You may also be interested in...
The European Commission has approved Abbott Laboratories' pending acquisition of Alere, on condition that Alere's Epoc, Triage and BNP businesses are divested to alleviate anti-trust concerns. However, Abbott is still looking to cut loose from the $5.8bn deal.
Poor access to bone densitometry is the main reason why less than one in five of people with ostoeoporosis in Spain are aware of their condition. The problem is exacerbated by low rates of preventive screening.
In this roundup feature focusing on developments in digital health, Medtech Insight highlights interviews with Medtronic, Abbott and Congenica, partnerships and launches, and AI and cybersecurity announcements from November.